Advanced Biomedical Research

Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial

Authors

1 Department of Clinical Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Epidemiology, School of Health and Nutrition, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Cachexia can occur as part of many end-stage or chronic diseases, and chronic obstructive pulmonary disease. This study was aimed to evaluate the effect of Pentoxifylline in patients with cancer cachexia.
Materials and Methods: The present study was conducted as a double-blind randomized controlled trial on 70 patients with advanced malignancy who loss of >5% of ideal or preillness body weight in the previous 2 months. Patients were assessed in two groups: case group, under treatment, using Pentoxifylline (400 mg) three times a day, for 2 months, and in the control group, patients received placebo. Age, sex, weight change, change in arm circumference and quality of life were assessed at baseline, week-4 and week-8.




Results: The mean age of the patients was 56 ± 17.3 years and 47% were female. Weight and arm circumference decreased during follow-up in both groups, but these differences between case and controls were not statistically significant. Quality of life (QOL) score in the case group improved after 4 weeks then decreased at the end of treatment but in the control group QOL score decreased during 2 month treatment. In week-4 patients in the case group significantly reported higher score of QOL compare to patients in the control group (P = 0.029).
Conclusion: Results of this study demonstrated that Pentoxifylline in the treatment of cancer cachexia did not have any effect in weight gain and arm circumference in cachectic patients. But in short-term (1 month) treatment, QOL was improved in these patients. And after 2 month treatment this was not effective compared to placebo.

Keywords

1.
Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 2001;93:380-3.  Back to cited text no. 1
    
2.
Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009;89:381-410.  Back to cited text no. 2
    
3.
DonohoeCL, Ryan AM, Reynolds JV. Cancer cachexia: Mechanisms and clinical implications. Gastroenterol Res Pract 2011;2011:601434.  Back to cited text no. 3
    
4.
Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Dessì M, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010;15:200-11.  Back to cited text no. 4
    
5.
Khan ZH, Simpson EJ, Cole AT, Holt M, MacDonald I, Pye D, et al. Oesophageal cancer and cachexia: The effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003;17:677-82.  Back to cited text no. 5
    
6.
Argilés JM, Busquets S, García-Martínez C, López-Soriano FJ. Mediators involved in the cancer anorexia-cachexia syndrome: Past, present, and future. Nutrition 2005;21:977-85.  Back to cited text no. 6
    
7.
Fearon KC, Voss AC, Hustead DS;Cancer Cachexia Study Group. Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006;83:1345-50.  Back to cited text no. 7
    
8.
Richey LM, George JR, Couch ME, Kanapkey BK, Yin X, Cannon T, et al. Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:6561-7.  Back to cited text no. 8
    
9.
Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49 Suppl 2:35-42.  Back to cited text no. 9
    
10.
Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 1990;51:241-7.  Back to cited text no. 10
    
11.
Inui A. Cancer anorexia-cachexia syndrome: Current issues in research and management. CA Cancer J Clin 2002;52:72-91.  Back to cited text no. 11
    
12.
Bennani-Baiti N, Walsh D. What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb 2009;39:257-62.  Back to cited text no. 12
    
13.
Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2:862-71.  Back to cited text no. 13
    
14.
Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am 2002;16:589-617.  Back to cited text no. 14
    
15.
Argilés JM, BusquetsS, Felipe A, López-Soriano FJ. Muscle wasting in cancer and ageing: Cachexia versus sarcopenia. Adv Gerontol 2006;18:39-54.  Back to cited text no. 15
    
16.
Giordano KF, Jatoi A. The cancer anorexia/weight loss syndrome: Therapeutic challenges. Curr Oncol Rep 2005;7:271-6.  Back to cited text no. 16
    
17.
Uomo G, Gallucci F, Rabitti PG. Anorexia-cachexia syndrome in pancreatic cancer: Recent development in research and management. JOP 2006;7:157-62.  Back to cited text no. 17
[PUBMED]    
18.
Bennani-Baiti N, Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care 2008;25:407-11.  Back to cited text no. 18
    
19.
Persson C, Glimelius B. The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 2002;22:3661-8.  Back to cited text no. 19
    
20.
Scott HR, McMillan DC, Brown DJ, Forrest LM, McArdle CS, Milroy R. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 2003;40:295-9.  Back to cited text no. 20
    
21.
Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: Common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol 2008;101:8-10E.  Back to cited text no. 21
    
22.
Boddaert MS, Gerritsen WR, Pinedo HM. On our way to targeted therapy for cachexia in cancer? Curr Opin Oncol 2006;18:335-40.  Back to cited text no. 22
    
23.
Fox KM, Brooks JM, Gandra SR, Markus R, Chiou CF. Estimation of cachexia among cancer patients based on four definitions. J Oncol 2009;2009:693458.  Back to cited text no. 23
    
24.
McLaughlin CL, Rogan GJ, Tou J, Baile CA, Joy WD. Food intake and body temperature responses of rats to recombinant human inter leukin-1 beta and a tripeptide inter leukin-1 beta antagonist. Physiol Behav 1992;52:1155-60.  Back to cited text no. 24
    
25.
Perboni S, Inui A. Anorexia in cancer: Role of feeding-regulatory peptides. Philos Trans R Soc Lond B Biol Sci 2006;361:1281-9.  Back to cited text no. 25
    
26.
Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 2001;21:1355-8.  Back to cited text no. 26
    
27.
Plata-Salamán CR, Oomura Y, Kai Y. Tumor necros is factor and inter leukin-1 beta: Suppression of food in take by directaction in the central nervous system. Brain Res 1988;448:106-14.  Back to cited text no. 27
    
28.
Banks WA. Anorectic effects of calculating cytokines: Role of the vascular blood-brainbarrier. Nutrition 2001;17:434-7.  Back to cited text no. 28
    
29.
Hellerstein MK, Meydani S, Meydani M, Wu K, Dinarello CA. Interleukin-1-inducedanorexiaintherat. Influence of prostaglandins. J Clin Invest 1989;84:228-35.  Back to cited text no. 29
    
30.
Strassmann G, Kambayashi T. Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther 1995;1:107-13.  Back to cited text no. 30
    
31.
Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856-9.  Back to cited text no. 31
    
32.
Mantovani G, Madeddu C. Cancer cachexia: Medical management. Support Care Cancer 2010;18:1-9.  Back to cited text no. 32
    
33.
Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.  Back to cited text no. 33
    
34.
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-306.  Back to cited text no. 34
    
35.
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-73.  Back to cited text no. 35
    
36.
Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Santona MC, et al. Megestrol acetate in neoplastic anorexia/cachexia: Clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995;25:135-41.  Back to cited text no. 36
    
37.
Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007;CD004597.  Back to cited text no. 37
    
38.
Gordon JN, TrebbleTM. Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial. Gut 2005;54:540-5.  Back to cited text no. 38
    
39.
Balázs C, Kiss E. Immunological aspects of the effect of pentoxifylline (trental) (a brief review). Acta Microbiol Immunol Hung 1994;41:121-6.  Back to cited text no. 39
Advanced Biomedical Research
Volume 2016, March
March 2016
Pages 1-6